GlassScriptPhysician profile
Willliam C Wigington
NPI 1114028701
$5,609.19
in general payments reported to CMS, 2019-2025
33 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $748 · 2021: $1,216 · 2022: $884 · 2023: $710 · 2024: $692 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,771.66 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $477.54 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $456.94 | 2019-2025 | |
| Janssen Biotech, INC. | $336.12 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.13 | 2019-2022 | |
| Genzyme Corporation | $135.31 | 2022-2025 | |
| Qol Medical, LLC | $118.11 | 2019-2024 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $117.96 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $111.31 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $87.25 | 2019-2022 | |
| Allergan, INC. | $75.46 | 2019-2020 | |
| Lilly USA, LLC | $74.44 | 2024-2025 | Omvoh |
| Cook Medical LLC | $50.40 | 2021-2023 | Hemospray |
| Laborie Medical Technologies Corp. | $45.88 | 2025 | |
| Aimmune Therapeutics, INC. | $39.00 | 2025 | Vowst, Zenpep |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $38.88 | 2020 | |
| Intercept Pharmaceuticals, INC. | $38.82 | 2019 | |
| Medtronic, INC. | $28.72 | 2023 | Interstim |
| Amag Pharmaceuticals, INC. | $27.10 | 2022 | |
| Ironwood Pharmaceuticals, INC | $25.39 | 2019-2020 | |
| Amgen INC. | $24.54 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $24.21 | 2021 | |
| Ardelyx, INC. | $22.07 | 2025 | Ibsrela |
| Boston Scientific Corporation | $19.92 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.93 | 2024 | Voquezna |
| Micro-Tech Endoscopy USA, INC. | $15.80 | 2024 | Eyemax |
| Celgene Corporation | $15.42 | 2023 | |
| Madrigal Pharmaceuticals | $15.12 | 2025 | Rezdiffra |
| Celltrion USA INC. | $14.84 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $13.40 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.89 | 2023 | Cyltezo |
| Olympus America INC. | $12.18 | 2019 | |
| Echosens North America, INC. | $10.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willliam Wigington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.